The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma
This study aimed to investigate the activity of arsenic trioxide (As2O3) combined with ascorbic acid, ifosfamide, and prednisone chemotherapy in patients with repeatedly relapsed and refractory multiple myeloma (MM). Here, we retrospectively analyzed medical data of 30 MM patients showing progressiv...
Main Authors: | Li, Xin, Sun, Wan-Jun |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399549/ |
Similar Items
-
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review
by: He, Xuepeng, et al.
Published: (2014) -
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014) -
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014) -
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Alegre, Adrian, et al.
Published: (2011) -
Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael, M, et al.
Published: (2010)